Target intelligence / Profile preview

Free iron (null)

Target
null
Molecular classification
Other
01

Overview

Free iron refers to iron ions that are not bound to protective proteins such as transferrin or ferritin, and instead exist in a chemically labile, reactive state either in plasma or inside cells[4][5][6][7][8]. Free iron is present at extremely low levels in healthy individuals because of its pronounced toxicity: it catalyzes the formation of highly reactive hydroxyl radicals (via the Fenton reaction), causes oxidative damage to lipids, proteins, and DNA, and can lead to cell death and tissue injury[4][8]. The major forms of free iron are unbound Fe2+ (ferrous) and Fe3+ (ferric) ions, collectively contributing to non-transferrin-bound iron (NTBI) in the bloodstream and to the "labile iron pool" (LIP) within cells[5][6][7]. Under physiological conditions, virtually all iron is tightly regulated and sequestered by protein carriers to avoid free iron toxicity[3][4]. While drugs exist to chelate excess free iron in pathological states (such as iron overload disorders), free iron itself is not considered a conventional molecular target (e.g., receptor, enzyme, transporter) in therapeutic development—instead, it is a biochemical hazard tightly controlled by the body[4][8].

Other names
Labile iron poolNon-transferrin-bound iron (NTBI)Unbound ironLabile plasma ironFree Fe2+Free Fe3+
02

Mechanism of action

Chelation and removal of free iron to reduce toxicity and lower oxidative stress

03

Biological functions

Oxidation–reduction reactionsGeneration of reactive oxygen speciesCellular toxicity (via Fenton reaction)Cofactor for iron-dependent enzymes only when incorporated (not as free iron)Oxygen/electron transport (by iron when appropriately bound)Regulation of iron homeostasis
04

Disease associations

Iron overload syndromes (e.g., hemochromatosis, thalassemia)Neurodegenerative diseases (via oxidative stress, e.g., Parkinson’s disease)Cancer (as a contributor to oxidative DNA damage)InflammationCardiovascular disease (by promoting oxidative tissue injury)Infection (supports microbial growth at sites of excess)
05

Safety considerations

High toxicity due to promotion of reactive oxygen species and cellular damageNarrow therapeutic window for chelator drugsRisk of over-chelation leading to iron deficiency and anemia
06

Interacting drugs

Deferoxamine

3 more in the full profile.

07

Biomarkers

Labile plasma iron (LPI)Non-transferrin-bound iron (NTBI)Serum ferritin (indirect, reflects storage not free iron)Transferrin saturation (indirect, reflects iron binding status)

Beyond the preview

Go deeper on Free iron (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Free iron (null).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call